Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma

TP53 mutations are ubiquitous in high‐grade serous ovarian carcinomas (HGSOC), and the presence of TP53 mutation discriminates between high and low‐grade serous carcinomas and is now an important biomarker for clinical trials targeting mutant p53. p53 immunohistochemistry (IHC) is widely used as a s...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The journal of pathology. Clinical research 2016-10, Vol.2 (4), p.247-258
Hauptverfasser:	Köbel, Martin, Piskorz, Anna M, Lee, Sandra, Lui, Shuhong, LePage, Cecile, Marass, Francesco, Rosenfeld, Nitzan, Mes Masson, Anne‐Marie, Brenton, James D
Format:	Artikel
Sprache:	eng
Schlagworte:	biomarker Biopsy Classification Clinical trials Consortia Deoxyribonucleic acid DNA Endometrial cancer endometrioid ovarian carcinoma high grade serous ovarian carcinoma Immunohistochemistry Medical research Mutation Next-generation sequencing Original Ovarian cancer Ovarian carcinoma p53 p53 Protein prediction Proteins Software Splicing TP53 Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!